trail neutralizing antibody  (R&D Systems)

Journal: International Journal of Molecular Sciences

Article Title: Electronic Cigarette Exposure Increases the Severity of Influenza a Virus Infection via TRAIL Dysregulation in Human Precision-Cut Lung Slices

doi: 10.3390/ijms24054295

Figure Lengend Snippet: TRAIL neutralizing antibody regulated influenza A virus (IAV) infection in human precision-cut lung slices (PCLS). PCLS were treated with IAV and E-juice (EJ) in the presence or absence of a TRAIL neutralizing antibody (50 ng/mL) and IgG control (50 ng/mL) for 24, 48, and 72 h. IAV load in supernatants ( A – C ) and lung tissue ( D ) was analyzed by RT-PCR. Cytotoxicity ( E ) was analyzed by the LDH assay. Each data point (colored dot) represents the average of 3 replicates from each respective individual donor ( n = 5 donors). Horizontal lines indicate mean ± SEM. Paired t -test was used to analyze the data.

Article Snippet: To demonstrate the role of TRAIL in viral infection, a TRAIL neutralizing antibody (50 ng/mL, Peprotech, Cranbury, NJ, USA) or an IgG antibody control (50 ng/mL, Jackson Immuno-research, West Grove, PA, USA) was added to PCLS exposed to 0.05% E-juice with or without IAV infection for up to 72 h. Similarly, recombinant human TRAIL (0.1–10 ng/mL, Peprotech, Cranbury, NJ, USA) or bovine serum albumin (BSA) was applied to PCLS exposed to E-juice with or without IAV infection.

Techniques: Virus, Infection, Control, Reverse Transcription Polymerase Chain Reaction, Lactate Dehydrogenase Assay

Journal: Cancers

Article Title: Downregulation of TRAIL-Receptor 1 Increases TGFβ Type II Receptor Expression and TGFβ Signalling Via MicroRNA-370-3p in Pancreatic Cancer Cells

doi: 10.3390/cancers10110399

Figure Lengend Snippet: Knockdown of TRAIL-R1 increases the abundance of TGFβ-RII in Panc1 cells. Panc1 cells were transfected with siRNA against TRAIL-R1 or with control siRNA for 72 h without ( A ) or with ( B ) exposure to a neutralizing antibody against TRAIL (anti-TRAIL, 10 µg/mL) or ( C ) recombinant TRAIL (10 ng/mL). The expression of TRAIL-R1 and TGFβ-RII was analysed by Western blotting in whole cell lysates. As control for equal gel loading, levels of β-actin were determined in parallel. The blots shown are representative of three independent experiments yielding very similar results. ( D ) Densitometry-based quantification of the Western blots shown in ( A ). Data were compiled from three independent experiments and represent the mean ± SD ( n = 3). ( E ) Densitometry-based quantification of the Western blots shown in ( B ). ( F ) Densitometry-based quantification of the Western blots shown in ( C ). The asterisks ( * ) in ( D – F ) indicate significance relative to the ctrl.-siRNA; n.s.: not significant.

Article Snippet: Cell-stimulating agents used were TGFβ1 (ReliaTech, Wolfenbüttel, Germany), recombinant human TRAIL (10 ng/mL; PeproTech, Hamburg, Germany) and neutralizing TRAIL antibody (anti-TRAIL) (10 µg/mL; R&D Systems).

Techniques: Transfection, Recombinant, Expressing, Western Blot